Literature DB >> 2425009

Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines.

C O Tacket, C Ferreccio, J B Robbins, C M Tsai, D Schulz, M Cadoz, A Goudeau, M M Levine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2425009     DOI： 10.1093/infdis/154.2.342

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  26 in total

1.  Outbreak of typhoid fever in vaccinated members of the French Armed Forces in the Ivory Coast.

Authors:  Rémy Michel; Eric Garnotel; André Spiegel; Marc Morillon; Pierre Saliou; Jean-Paul Boutin
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

2.  The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi.

Authors:  R Paul Wilson; Sebastian E Winter; Alanna M Spees; Maria G Winter; Jessalyn H Nishimori; Jesus F Sanchez; Sean-Paul Nuccio; Robert W Crawford; Çagla Tükel; Andreas J Bäumler
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

Review 3.  Commercializing diarrhea vaccines for travelers.

Authors:  Rosa López-Gigosos; Marina Segura-Moreno; Rosa Díez-Díaz; Elena Plaza; Alberto Mariscal
Journal:  Hum Vaccin Immunother       Date:  2014-02-04       Impact factor: 3.452

Review 4.  Salmonella Serogroup C: Current Status of Vaccines and Why They Are Needed.

Authors:  Fabien J Fuche; Ousmane Sow; Raphael Simon; Sharon M Tennant
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

Review 5.  Advances in vaccines for typhoid fever.

Authors:  A Gupta; S Jalla; S Sazawal; M K Bhan
Journal:  Indian J Pediatr       Date:  1994 Jul-Aug       Impact factor: 1.967

6.  Immunogenicity of Salmonella typhi Ty21a vaccine for young children.

Authors:  J R Murphy; L Grez; L Schlesinger; C Ferreccio; S Baqar; C Muñoz; S S Wasserman; G Losonsky; J G Olson; M M Levine
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

7.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

8.  Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.

Authors:  M M Levine; D Herrington; J R Murphy; J G Morris; G Losonsky; B Tall; A A Lindberg; S Svenson; S Baqar; M F Edwards
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines.

Authors:  R D'Amelio; A Tagliabue; L Nencioni; A Di Addario; L Villa; M Manganaro; D Boraschi; S Le Moli; R Nisini; P M Matricardi
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

10.  Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

Authors:  S C Szu; D N Taylor; A C Trofa; J D Clements; J Shiloach; J C Sadoff; D A Bryla; J B Robbins
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.